Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 1997

View Archived Issues

Sankyo prepares ACAT inhibitors

Sumitomo reveals antipsychotic agents with reduced side effects

Taiho discloses antiangiogenic agents

Hypoglycemic/hypolipidemic agents from Kyorin

Novel antibiotic isolated by Kitasato Institute and Chinese Academy of Medical Science

Kitasato Institute discovers inhibitor of IL-6 activity

Cysteine protease inhibitors described by Senju

Novel recombinant protein for bone diseases from Hoechst

Fujisawa obtains natural antifungal agent

PGD2 antagonists claimed by Shionogi

Research on cardiovascular drugs reported at the meeting of the Japanese Circulation Society

Antidepressant effects of NKH-477

ME-3167 heading for NDA submission

Meiji Seika antibiotic scheduled for launch in Europe in 1998

Novel antipsychotic agent reported by Asahi Chemical

DepoTech's new formulation of morphine sulfate enters phase I

Cor Therapeutics receives nonapprovable letter for Integrilin NDA

Cubist Pharmaceuticals and Genzyme enter compound library screening collaboration

Aphton issued U.S. patents covering Gastrimmune

Synsorb Cd enters phase II

Cangene signs distribution agreement for WinRho SDF

Biogen licenses Hirulog

Luvox cleared for OCD in children and adolescents

Axcan receives approvable letter for URSO from FDA

U.S. patent covers Connetics TCR vaccine technology

Biological role of CD39 uncovered by Immunex and collaborators

Subcutaneous IL-2 boosts CD4 cell counts in HIV-infected patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.